This inventor holds 1 USPTO granted patent and 5 published patent applications, plus 1 CIPO patent. Top assignee: Ascendis Pharma Growth Disorders A/s. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Frank Faltinger: Innovator in Controlled-Release CNP Agonists
Introduction
Frank Faltinger is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled-release CNP agonists. His work focuses on creating innovative solutions that enhance therapeutic efficacy while minimizing side effects.
Latest Patents
Frank Faltinger holds 1 patent for his invention titled "Controlled-release CNP agonists with low NPR-C binding." This patent relates to a controlled-release CNP agonist characterized by low NPR-C affinity. The invention includes pharmaceutical compositions that comprise this controlled-release CNP agonist, detailing their use and methods of treatment.
Career Highlights
Frank Faltinger is currently associated with Ascendis Pharma Growth Disorders A/S, where he continues to advance his research and development efforts. His expertise in pharmacology and innovative drug design has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Throughout his career, Frank has collaborated with esteemed colleagues such as Harald Rau and Ulrich Hersel. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the advancement of scientific knowledge.
Conclusion
Frank Faltinger exemplifies the spirit of innovation in the pharmaceutical sector through his groundbreaking work on controlled-release CNP agonists. His contributions not only enhance treatment options but also pave the way for future advancements in drug development.